BioCentury
ARTICLE | Clinical News

CG400549: Phase I data

May 17, 2010 7:00 AM UTC

In a European Phase I trial in 42 healthy volunteers, single-ascending doses of oral CG400549 were well tolerated with no drug-related adverse events reported. The company plans to start a Phase I tri...